Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2013, Article ID 168039, 15 pages
http://dx.doi.org/10.1155/2013/168039
Review Article

Diabetic Neuropathy and Oxidative Stress: Therapeutic Perspectives

1Razi Drug Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran
2Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 1417614411, Iran

Received 16 December 2012; Revised 22 February 2013; Accepted 18 March 2013

Academic Editor: Grzegorz A. Czapski

Copyright © 2013 Asieh Hosseini and Mohammad Abdollahi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Peripheral Neuropathy,” http://courses.washington.edu/conj/neuron/peripheralNeuropathy.htm.
  2. V. Bril, “Treatments for DN,” Journal of the Peripheral Nervous System, vol. 2, pp. 22–27, 2012. View at Google Scholar
  3. B. C. Callaghan, H. T. Cheng, C. L. Stables, A. L. Smith, and E. L. Feldman, “Diabetic neuropathy: clinical manifestations and current treatments,” The Lancet Neurology, vol. 11, no. 6, pp. 521–534, 2012. View at Google Scholar
  4. S. Tesfaye and D. Selvarajah, “Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy,” Diabetes—Metabolism Research and Reviews, vol. 1, pp. 8–14, 2012. View at Google Scholar
  5. P. K. Thomas, “Classification, differential diagnosis, and staging of diabetic peripheral neuropathy,” Diabetes, vol. 46, no. 2, pp. S54–S57, 1997. View at Google Scholar · View at Scopus
  6. A. J. M. Boulton, A. I. Vinik, J. C. Arezzo et al., “Diabetic neuropathies: a statement by the American Diabetes Association,” Diabetes Care, vol. 28, no. 4, pp. 956–962, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Tesfaye, A. J. M. Boulton, P. J. Dyck et al., “Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments,” Diabetes Care, vol. 33, no. 10, pp. 2285–2293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Negi, A. Kumar, R. P. Joshi, P. K. Ruby, and S. S. Sharma, “Oxidative stress and diabetic neuropathy: current status of antioxidants,” Institute of Integrative Omics and Applied Biotechnology, vol. 2, no. 6, pp. 71–78, 2011. View at Google Scholar
  9. J. L. Edwards, A. M. Vincent, H. T. Cheng, and E. L. Feldman, “Diabetic neuropathy: mechanisms to management,” Pharmacology & Therapeutics, vol. 120, no. 1, pp. 1–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Mahmood, B. K. Singh, and M. Akhtar, “Diabetic neuropathy: therapies on the horizon,” Journal of Pharmacy and Pharmacology, vol. 61, no. 9, pp. 1137–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Rajbhandari and M. K. Piya, “A brief review on the pathogenesis of human diabetic neuropathy: observations and postulations,” International Journal of Diabetes and Metabolism, vol. 13, no. 3, pp. 135–140, 2005. View at Google Scholar · View at Scopus
  12. S. Yagihashi, H. Mizukami, and K. Sugimoto, “Mechanism of diabetic neuropathy: where are we now and where to go?” Journal of Diabetes Investigation, vol. 2, no. 1, pp. 18–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. A. Head, “Peripheral neuropathy: pathogenic mechanisms and alternative therapies,” Alternative Medicine Review, vol. 11, no. 4, pp. 294–329, 2006. View at Google Scholar · View at Scopus
  14. J. Shakher and M. J. Stevens, “Update on the management of diabetic polyneuropathies,” Diabetes, Metabolic Syndrome and Obesity, vol. 4, pp. 289–305, 2011. View at Google Scholar
  15. M. B. Max, “Endogenous monoamine analgesic systems: amitriptyline in painful diabetic neuropathy,” Anesthesia Progress, vol. 34, no. 4, pp. 123–127, 1987. View at Google Scholar · View at Scopus
  16. M. B. Max, M. Culnane, and S. C. Schafer, “Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood,” Neurology, vol. 37, no. 4, pp. 589–596, 1987. View at Google Scholar · View at Scopus
  17. M. B. Max, S. A. Lynch, J. Muir, S. E. Shoaf, B. Smoller, and R. Dubner, “Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy,” The New England Journal of Medicine, vol. 326, no. 19, pp. 1250–1256, 1992. View at Google Scholar · View at Scopus
  18. M. Vrethem, J. Boivie, H. Arnqvist, H. Holmgren, T. Lindström, and L. H. Thorell, “A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,” Clinical Journal of Pain, vol. 13, no. 4, pp. 313–323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Morello, S. G. Leckband, C. P. Stoner, D. F. Moorhouse, and G. A. Sahagian, “Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,” Archives of Internal Medicine, vol. 159, no. 16, pp. 1931–1937, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. H. Sindrup, L. F. Gram, T. Skjold, E. Grodum, K. Brøsen, and H. Beck-Nielsen, “Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study,” British Journal of Clinical Pharmacology, vol. 30, no. 5, pp. 683–691, 1990. View at Google Scholar · View at Scopus
  21. M. B. Max, R. Kishore-Kumar, S. C. Schafer et al., “Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial,” Pain, vol. 45, no. 1, pp. 3–9, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Kvinesdal, J. Molin, A. Frøland, and L. F. Gram, “Imipramine treatment of painful diabetic neuropathy,” Journal of the American Medical Association, vol. 251, no. 13, pp. 1727–1730, 1984. View at Publisher · View at Google Scholar · View at Scopus
  23. F. J. Gomez-Perez, J. A. Rull, H. Dies, J. G. Rodriquez-Rivera, J. Gonzalez-Barranco, and O. Lozano-Castañeda, “Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study,” Pain, vol. 23, no. 4, pp. 395–400, 1985. View at Google Scholar · View at Scopus
  24. S. H. Sindrup, U. Bjerre, A. Dejgaard, K. Brøsen, T. Aaes-Jørgensen, and L. F. Gram, “The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy,” Clinical Pharmacology and Therapeutics, vol. 52, no. 5, pp. 547–552, 1992. View at Google Scholar · View at Scopus
  25. D. A. Simpson, “Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy,” Journal of Clinical Neuromuscular Disease, vol. 3, no. 2, pp. 53–62, 2001. View at Google Scholar · View at Scopus
  26. S. H. Sindrup, F. W. Bach, C. Madsen, L. F. Gram, and T. S. Jensen, “Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial,” Neurology, vol. 60, no. 8, pp. 1284–1289, 2003. View at Google Scholar · View at Scopus
  27. M. C. Rowbotham, V. Goli, N. R. Kunz, and D. Lei, “Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study,” Pain, vol. 110, no. 3, pp. 697–706, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. K. Kadiroglu, D. Sit, H. Kayabasi, A. Kemal Tuzcu, N. Tasdemir, and M. E. Yilmaz, “The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus,” Journal of Diabetes and its Complications, vol. 22, no. 4, pp. 241–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Raskin, Y. L. Pritchett, F. Wang et al., “A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain,” Pain Medicine, vol. 6, no. 5, pp. 346–356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Goldstein, Y. Lu, M. J. Detke, T. C. Lee, and S. Iyengar, “Duloxetine vs. placebo in patients with painful diabetic neuropathy,” Pain, vol. 116, no. 1-2, pp. 109–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. F. Wernicke, Y. L. Pritchett, D. N. D'Souza et al., “A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,” Neurology, vol. 67, no. 8, pp. 1411–1420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. K. Kajdasz, S. Iyengar, D. Desaiah et al., “Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies,” Clinical Therapeutics, vol. 29, no. 11, pp. 2536–2546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Lesser, U. Sharma, L. LaMoreaux, and R. M. Poole, “Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial,” Neurology, vol. 63, no. 11, pp. 2104–2110, 2004. View at Google Scholar · View at Scopus
  34. J. Rosenstock, M. Tuchman, L. Lamoreaux, and U. Sharma, “Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial,” Pain, vol. 110, no. 3, pp. 628–638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. R. W. Richter, R. Portenoy, U. Sharma, L. Lamoreaux, H. Bockbrader, and L. E. Knapp, “Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial,” Journal of Pain, vol. 6, no. 4, pp. 253–260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Freynhagen, K. Strojek, T. Griesing, E. Whalen, and M. Balkenohl, “Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens,” Pain, vol. 115, no. 3, pp. 254–263, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Tölle, R. Freynhagen, M. Versavel, U. Trostmann, and J. P. Young Jr., “Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study,” European Journal of Pain, vol. 12, no. 2, pp. 203–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. C. Arezzo, J. Rosenstock, L. LaMoreaux, and L. Pauer, “Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial,” BMC Neurology, vol. 8, article 33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Freeman, E. Durso-DeCruz, and B. Emir, “Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses,” Diabetes Care, vol. 31, no. 7, pp. 1448–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Backonja, A. Beydoun, K. R. Edwards et al., “Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial,” Journal of the American Medical Association, vol. 280, no. 21, pp. 1831–1836, 1998. View at Google Scholar · View at Scopus
  41. K. C. Gorson, C. Schott, R. Herman, A. H. Ropper, and W. M. Rand, “Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 2, pp. 251–252, 1999. View at Google Scholar · View at Scopus
  42. D. K. Kochar, N. Jain, R. P. Agarwal, T. Srivastava, P. Agarwal, and S. Gupta, “Sodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled study,” Acta Neurologica Scandinavica, vol. 106, no. 5, pp. 248–252, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. D. K. Kochar, N. Rawat, R. P. Agrawal et al., “Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study,” QJM, vol. 97, no. 1, pp. 33–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Otto, F. W. Bach, T. S. Jensen, and S. H. Sindrup, “Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial,” Neurology, vol. 62, no. 2, pp. 285–288, 2004. View at Google Scholar · View at Scopus
  45. E. Eisenberg, Y. Lurie, C. Braker, D. Daoud, and A. Ishay, “Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study,” Neurology, vol. 57, no. 3, pp. 505–509, 2001. View at Google Scholar · View at Scopus
  46. A. I. Vinik, M. Tuchman, B. Safirstein et al., “Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies,” Pain, vol. 128, no. 1-2, pp. 169–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. V. M. Jose, A. Bhansali, D. Hota, and P. Pandhi, “Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,” Diabetic Medicine, vol. 24, no. 4, pp. 377–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. A. Rull, R. Quibrera, H. González-Millán, and O. L. Castañeda, “Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial,” Diabetologia, vol. 5, no. 4, pp. 215–218, 1969. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Dogra, S. Beydoun, J. Mazzola, M. Hopwood, and Y. Wan, “Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study,” European Journal of Pain, vol. 9, no. 5, pp. 543–554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Beydoun, A. Shaibani, M. Hopwood, and Y. Wan, “Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study,” Acta Neurologica Scandinavica, vol. 113, no. 6, pp. 395–404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Grosskopf, J. Mazzola, Y. Wan, and M. Hopwood, “A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy,” Acta Neurologica Scandinavica, vol. 114, no. 3, pp. 177–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. R. L. Rauck, A. Shaibani, V. Biton, J. Simpson, and B. Koch, “Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study,” Clinical Journal of Pain, vol. 23, no. 2, pp. 150–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. J. P. Wymer, J. Simpson, D. Sen, and S. Bongardt, “Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens,” Clinical Journal of Pain, vol. 25, no. 5, pp. 376–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Harati, C. Gooch, M. Swenson et al., “Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy,” Neurology, vol. 50, no. 6, pp. 1842–1846, 1998. View at Google Scholar · View at Scopus
  55. S. H. Sindrup, G. Andersen, C. Madsen, T. Smith, K. Brøsen, and T. S. Jensen, “Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial,” Pain, vol. 83, no. 1, pp. 85–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Freeman, P. Raskin, D. J. Hewitt et al., “Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 147–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. J. S. Gimbel, P. Richards, and R. K. Portenoy, “Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial,” Neurology, vol. 60, no. 6, pp. 927–934, 2003. View at Google Scholar · View at Scopus
  58. C. P. N. Watson, D. Moulin, J. Watt-Watson, A. Gordon, and J. Eisenhoffer, “Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy,” Pain, vol. 105, no. 1-2, pp. 71–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Hanna, C. O'Brien, and M. C. Wilson, “Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients,” European Journal of Pain, vol. 12, no. 6, pp. 804–813, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Gilron, J. M. Bailey, D. Tu, R. R. Holden, D. F. Weaver, and R. L. Houlden, “Morphine, gabapentin, or their combination for neuropathic pain,” The New England Journal of Medicine, vol. 352, no. 13, pp. 1324–1334, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. “Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group,” Archives of Internal Medicine, vol. 151, no. 11, pp. 2225–2229, 1991. View at Publisher · View at Google Scholar · View at Scopus
  62. N. M. Scheffler, P. L. Sheitel, and M. N. Lipton, “Treatment of painful diabetic neuropathy with capsaicin 0.075%,” Journal of the American Podiatric Medical Association, vol. 81, no. 6, pp. 288–293, 1991. View at Google Scholar · View at Scopus
  63. R. Tandan, G. A. Lewis, P. B. Krusinski, G. B. Badger, and T. J. Fries, “Topical capsaicin in painful diabetic neuropathy,” Diabetes Care, vol. 15, no. 1, pp. 8–14, 1992. View at Google Scholar · View at Scopus
  64. “Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group,” Diabetes Care, vol. 15, no. 2, pp. 159–165, 1992. View at Scopus
  65. K. C. J. Yuen, N. R. Baker, and G. Rayman, “Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study,” Diabetes Care, vol. 25, no. 10, pp. 1699–1703, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. R. P. Agrawal, R. Choudhary, P. Sharma et al., “Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 161–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Meier, G. Wasner, M. Faust et al., “Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study,” Pain, vol. 106, no. 1-2, pp. 151–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. R. L. Barbano, D. N. Herrmann, S. Hart-Gouleau, J. Pennella-Vaughan, P. A. Lodewick, and R. H. Dworkin, “Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy,” Archives of Neurology, vol. 61, no. 6, pp. 914–918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Dejgard, J. Kastrup, and P. Petersen, “Mexiletine for treatment of chronic painful diabetic neuropathy,” Lancet, vol. 1, no. 8575-8576, pp. 9–11, 1988. View at Google Scholar · View at Scopus
  70. P. Oskarsson, J. G. Ljunggren, and P. E. Lins, “Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy,” Diabetes Care, vol. 20, no. 10, pp. 1594–1597, 1997. View at Google Scholar · View at Scopus
  71. J. M. Wright, J. C. Oki, and L. Graves, “Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy,” Annals of Pharmacotherapy, vol. 31, no. 1, pp. 29–34, 1997. View at Google Scholar · View at Scopus
  72. K. A. Nelson, K. M. Park, E. Robinovitz, C. Tsigos, and M. B. Max, “High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia,” Neurology, vol. 48, no. 5, pp. 1212–1218, 1997. View at Google Scholar · View at Scopus
  73. C. N. Sang, S. Booher, I. Gilron, S. Parada, and M. B. Max, “Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials,” Anesthesiology, vol. 96, no. 5, pp. 1053–1061, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Ranoux, N. Attal, F. Morain, and D. Bouhassira, “Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain,” Annals of Neurology, vol. 64, no. 3, pp. 274–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Y. Yuan, J. J. Sheu, J. M. Yu et al., “Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial,” Neurology, vol. 72, no. 17, pp. 1473–1478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. A. F. Sima, M. Calvani, M. Mehra, and A. Amato, “Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials,” Diabetes Care, vol. 28, no. 1, pp. 89–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Ziegler, M. Hanefeld, K. J. Ruhnau et al., “Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy,” Diabetes Care, vol. 22, no. 8, pp. 1296–1301, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Ziegler, H. Nowak, P. Kempler, P. Vargha, and P. A. Low, “Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis,” Diabetic Medicine, vol. 21, no. 2, pp. 114–121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Yu, L. Zhang, X. Yang et al., “Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1α-Sirt3 axis,” Molecules, vol. 17, no. 9, pp. 11216–11228, 2012. View at Google Scholar
  80. L. J. Coppey, A. Holmes, E. P. Davidson, and M. A. Yorek, “Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat,” Journal of Nutrition and Metabolism, vol. 2012, Article ID 950517, 8 pages, 2012. View at Publisher · View at Google Scholar
  81. S. Ahn and R. Song, “Effects of Tai Chi Exercise on glucose control, neuropathy scores, balance, and quality of life in patients with type 2 diabetes and neuropathy,” Journal of Alternative and Complementary Medicine, vol. 18, no. 12, pp. 1172–1178, 2012. View at Publisher · View at Google Scholar
  82. S. Shin, K. J. Kim, H. J. Chang et al., “The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial,” Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 185–188, 2012. View at Publisher · View at Google Scholar
  83. A. K. Schreiber, M. Neufeld, C. H. Jesus, and J. M. Cunha, “Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats,” Neuropharmacology, vol. 63, no. 8, pp. 1286–1297, 2012. View at Google Scholar
  84. L. Wang, M. Chopp, A. Szalad et al., “Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice,” Neurobiology of Disease, vol. 48, no. 3, pp. 546–555, 2012. View at Publisher · View at Google Scholar
  85. W. Sun, B. Miao, X. C. Wang et al., “Gastrodin inhibits allodynia and hyperalgesia in painful DN rats by decreasing excitability of nociceptive primary sensory neurons,” PLoS ONE, vol. 7, no. 6, Article ID e39647, 2012. View at Google Scholar
  86. N. Hotta, R. Kawamori, M. Fukuda, and Y. Shigeta, “Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy,” Diabetic Medicine, vol. 29, no. 12, pp. 1529–1533, 2012. View at Google Scholar
  87. H. N. Attia, N. M. Al-Rasheed, N. M. Al-Rasheed, Y. A. Maklad, A. A. Ahmed, and S. A. Kenawy, “Protective effects of combined therapy of gliclazide with curcumin in experimental DN in rats,” Behavioural Pharmacology, vol. 23, no. 2, pp. 153–161, 2012. View at Google Scholar
  88. K. Naruse, J. Sato, M. Funakubo et al., “Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in DN,” PLoS ONE, vol. 6, no. 11, Article ID e27458, 2011. View at Google Scholar
  89. X. Xu, H. Jiang Liu, W. Zhang, X. Xu, and Z. Li, “The effects of galanin on dorsal root ganglion neurons with high glucose treatment in vitro,” Brain Research Bulletin, vol. 87, no. 1, pp. 85–93, 2012. View at Google Scholar
  90. M. A. Yorek, “Treatment of DN with baicalein: intervention at multiple sites,” Experimental Neurology, vol. 232, no. 2, pp. 105–109, 2011. View at Google Scholar
  91. G. D. Dalmolin, C. R. Silva, F. K. Rigo et al., “Antinociceptive effect of Brazilian armed spider venom toxin Tx3-3 in animal models of neuropathic pain,” Pain, vol. 152, no. 10, pp. 2224–2232, 2011. View at Publisher · View at Google Scholar
  92. A. Hosseini, M. Sharifzadeh, S. M. Rezayat et al., “Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathy,” International Journal of Nanomedicine, vol. 5, no. 1, pp. 517–523, 2010. View at Google Scholar · View at Scopus
  93. A. Hosseini, M. Abdollahi, G. Hassanzadeh et al., “Protective effect of magnesium-25 carrying porphyrin-fullerene nanoparticles on degeneration of dorsal root ganglion neurons and motor function in experimental DN,” Basic & Clinical Pharmacology & Toxicology, vol. 109, no. 5, pp. 381–386, 2011. View at Publisher · View at Google Scholar
  94. E. Milani, S. Nikfar, R. Khorasani, M. J. Zamani, and M. Abdollahi, “Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats,” Comparative Biochemistry and Physiology Part C, vol. 140, no. 2, pp. 251–255, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Larijani, M. Salimi, N. Pourkhalili et al., “Positive response of isolated rat pancreatic islets to IMOD; hopes for better transplant outcome and graft function,” Asian Journal of Animal and Veterinary Advances, vol. 6, no. 10, pp. 1019–1025, 2011. View at Publisher · View at Google Scholar
  96. A. Hosseini and M. Abdollahi, “It is time to formulate an antioxidant mixture for management of diabetes and its complications: notice for phannaceutical industries,” International Journal of Pharmacology, vol. 8, no. 1, pp. 60–61, 2012. View at Google Scholar
  97. A. Hosseini and M. Abdollahi, “Through a mechanism-based approach, nanoparticles of cerium and yttrium may improve the outcome of pancreatic islet isolation,” Journal of Medical Hypotheses and Ideas, vol. 6, pp. 4–6, 2012. View at Google Scholar
  98. T. S. Jensen, M. M. Backonja, S. Hernández Jiménez, S. Tesfaye, P. Valensi, and D. Ziegler, “New perspectives on the management of diabetic peripheral neuropathic pain,” Diabetes and Vascular Disease Research, vol. 3, no. 2, pp. 108–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. T. J. Lindsay, B. C. Rodgers, V. Savath, and K. Hettinger, “Treating diabetic peripheral neuropathic pain,” American Family Physician, vol. 82, no. 2, pp. 151–158, 2010. View at Google Scholar · View at Scopus
  100. N. B. Finnerup, M. Otto, H. J. McQuay, T. S. Jensen, and S. H. Sindrup, “Algorithm for neuropathic pain treatment: an evidence based proposal,” Pain, vol. 118, no. 3, pp. 289–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Ziegler, “Painful diabetic neuropathy: advantage of novel drugs over old drugs?” Diabetes care, vol. 32, pp. S414–419, 2009. View at Google Scholar · View at Scopus
  102. A. Sultan, H. Gaskell, S. Derry, and R. A. Andrew, “Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials,” BMC Neurology, vol. 8, article 29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Devitt, “AAN, AANEM, and AAPMR publish guideline for treatment of painful diabetic neuropath,” American Family Physician, vol. 86, no. 5, pp. 469–470, 2012. View at Google Scholar
  104. S. Seidel, M. Aigner, M. Ossege, E. Pernicka, B. Wildner, and T. Sycha, “Antipsychotics for acute and chronic pain in adults,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004844, 2008. View at Google Scholar · View at Scopus
  105. T. J. Lindsay, K. vitrikas, M. Temporal, and C. M. Herndon, “Diabetic neuropathic pain: real world treatment options,” Clinical Medicine Insights: Therapeutics, vol. 4, pp. 169–183, 2012. View at Google Scholar
  106. A. I. Vinik, V. Bril, P. Kempler et al., “Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial,” Clinical Therapeutics, vol. 27, no. 8, pp. 1164–1180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. N. Hotta, T. Toyota, K. Matsuoka et al., “Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study,” Diabetes Care, vol. 24, no. 10, pp. 1776–1782, 2001. View at Google Scholar · View at Scopus
  108. N. Hotta, Y. Akanuma, R. Kawamori et al., “Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial,” Diabetes Care, vol. 29, no. 7, pp. 1538–1544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. V. Bril, T. Hirose, S. Tomioka, and R. Buchanan, “Ranirestat for the management of diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 32, no. 7, pp. 1256–1260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Haupt, H. Ledermann, and W. Köpcke, “Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study),” International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 2, pp. 71–77, 2005. View at Google Scholar · View at Scopus
  111. R. Rahimi, S. Nikfar, B. Larijani, and M. Abdollahi, “A review on the role of antioxidants in the management of diabetes and its complications,” Biomedicine and Pharmacotherapy, vol. 59, no. 7, pp. 365–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. S. S. M. S. Monfared, B. Larijani, and M. Abdollahi, “Islet transplantation and antioxidant management: a comprehensive review,” World Journal of Gastroenterology, vol. 15, no. 10, pp. 1153–1161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Hasani-Ranjbar, B. Larijani, and M. Abdollah, “A systematic review of iranian medicinal plants useful in diabetes mellitus,” Archives of Medical Science, vol. 4, no. 3, pp. 285–292, 2008. View at Google Scholar · View at Scopus
  114. O. Tabatabaei-Malazy, B. Larijani, and M. Abdollahi, “A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans islets,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 15, no. 3, pp. 447–466, 2012. View at Google Scholar
  115. S. Momtaz and M. Abdollahi, “An update on pharmacology of Satureja species; from antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulation,” International Journal of Pharmacology, vol. 6, no. 4, pp. 454–461, 2010. View at Google Scholar · View at Scopus
  116. A. Mehri, S. Hasani-Ranjbar, B. Larijani, and M. Abdollahi, “A systematic review of efficacy and safety of urtica dioica in the treatment of diabetes,” International Journal of Pharmacology, vol. 7, no. 2, pp. 161–170, 2011. View at Publisher · View at Google Scholar · View at Scopus